These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35008383)

  • 21. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
    Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
    Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
    Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
    Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of miR-193a-5p and miR-146 a-5p Expression Induces G1 Arrest in Colorectal Cancer through Targeting of MDM2/p53.
    Noorolyai S; Baghbani E; Aghebati Maleki L; Baghbanzadeh Kojabad A; Shanehbansdi D; Khaze Shahgoli V; Mokhtarzadeh A; Baradaran B
    Adv Pharm Bull; 2020 Jan; 10(1):130-134. PubMed ID: 32002372
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors.
    Li H; Zhang J; Tong JHM; Chan AWH; Yu J; Kang W; To KF
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
    Kannan S; Partridge AW; Lane DP; Verma CS
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1.
    Zhang J; Sun W; Kong X; Zhang Y; Yang HJ; Ren C; Jiang Y; Chen M; Chen X
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24259-24267. PubMed ID: 31712410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zinc-finger protein p52-ZER6 accelerates colorectal cancer cell proliferation and tumour progression through promoting p53 ubiquitination.
    Huang C; Wu S; Li W; Herkilini A; Miyagishi M; Zhao H; Kasim V
    EBioMedicine; 2019 Oct; 48():248-263. PubMed ID: 31521611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of mitochondrial membrane-linked SAB determines severity of sex-dependent acute liver injury.
    Win S; Min RW; Chen CQ; Zhang J; Chen Y; Li M; Suzuki A; Abdelmalek MF; Wang Y; Aghajan M; Aung FW; Diehl AM; Davis RJ; Than TA; Kaplowitz N
    J Clin Invest; 2019 Dec; 129(12):5278-5293. PubMed ID: 31487267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression.
    Wang S; Zhang Y; Huang J; Wong CC; Zhai J; Li C; Wei G; Zhao L; Wang G; Wei H; Zhao Z; Yu J
    Cancer Res; 2019 Aug; 79(16):4086-4098. PubMed ID: 31239268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolyl hydroxylase 3 stabilizes the p53 tumor suppressor by inhibiting the p53-MDM2 interaction in a hydroxylase-independent manner.
    Xu Y; Gao Q; Xue Y; Li X; Xu L; Li C; Qin Y; Fang J
    J Biol Chem; 2019 Jun; 294(25):9949-9958. PubMed ID: 31092600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hsp70- and Hsp90-Mediated Regulation of the Conformation of p53 DNA Binding Domain and p53 Cancer Variants.
    Boysen M; Kityk R; Mayer MP
    Mol Cell; 2019 May; 74(4):831-843.e4. PubMed ID: 31027880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coordinated Conformational Processing of the Tumor Suppressor Protein p53 by the Hsp70 and Hsp90 Chaperone Machineries.
    Dahiya V; Agam G; Lawatscheck J; Rutz DA; Lamb DC; Buchner J
    Mol Cell; 2019 May; 74(4):816-830.e7. PubMed ID: 31027879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The multiple mechanisms that regulate p53 activity and cell fate.
    Hafner A; Bulyk ML; Jambhekar A; Lahav G
    Nat Rev Mol Cell Biol; 2019 Apr; 20(4):199-210. PubMed ID: 30824861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers.
    Malekzadeh P; Pasetto A; Robbins PF; Parkhurst MR; Paria BC; Jia L; Gartner JJ; Hill V; Yu Z; Restifo NP; Sachs A; Tran E; Lo W; Somerville RP; Rosenberg SA; Deniger DC
    J Clin Invest; 2019 Mar; 129(3):1109-1114. PubMed ID: 30714987
    [No Abstract]   [Full Text] [Related]  

  • 35. First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
    Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M
    Mol Cancer Ther; 2019 Mar; 18(3):531-540. PubMed ID: 30679388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants.
    Omar SI; Tuszynski J
    Oncotarget; 2018 Dec; 9(98):37137-37156. PubMed ID: 30647850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
    Yang L; Song T; Cheng Q; Chen L; Chen J
    Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
    CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UBXN2A enhances CHIP-mediated proteasomal degradation of oncoprotein mortalin-2 in cancer cells.
    Sane S; Hafner A; Srinivasan R; Masood D; Slunecka JL; Noldner CJ; Hanson AD; Kruisselbrink T; Wang X; Wang Y; Yin J; Rezvani K
    Mol Oncol; 2018 Oct; 12(10):1753-1777. PubMed ID: 30107089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.